INFI | Infinity Pharmaceuticals, Inc.

Index- P/E- EPS (ttm)-0.48 Insider Own2.15% Shs Outstand89.41M Perf Week16.19%
Market Cap16.41M Forward P/E- EPS next Y-0.55 Insider Trans0.00% Shs Float88.23M Perf Month17.71%
Income-43.00M PEG- EPS next Q-0.12 Inst Own35.70% Short Float / Ratio0.70% / 0.72 Perf Quarter-23.72%
Sales2.70M P/S6.08 EPS this Y6.00% Inst Trans2.51% Short Interest0.62M Perf Half Y-67.18%
Book/sh-0.32 P/B- EPS next Y-19.60% ROA-92.60% Target Price- Perf Year-69.99%
Cash/sh- P/C- EPS next 5Y- ROE289.60% 52W Range0.12 - 1.76 Perf YTD-67.55%
Dividend- P/FCF- EPS past 5Y-22.60% ROI- 52W High-89.77% Beta1.36
Dividend %- Quick Ratio2.50 Sales past 5Y-15.40% Gross Margin39.70% 52W Low51.34% ATR0.02
Employees30 Current Ratio2.50 Sales Q/Q0.00% Oper. Margin- RSI (14)54.06 Volatility10.21% 9.12%
OptionableYes Debt/Eq- EPS Q/Q11.40% Profit Margin- Rel Volume0.50 Prev Close0.18
ShortableYes LT Debt/Eq- EarningsMar 28 AMC Payout- Avg Volume863.08K Price0.18
Recom3.00 SMA204.19% SMA506.90% SMA200-73.10% Volume427,676 Change-1.10%
Date Action Analyst Rating Change Price Target Change
Oct-18-21Initiated H.C. Wainwright Buy $9
Aug-02-21Upgrade JP Morgan Neutral → Overweight $6
Jul-28-21Upgrade Wells Fargo Equal Weight → Overweight $4 → $14
Jul-07-21Resumed B. Riley Securities Buy $7
Mar-18-21Initiated Truist Buy $12
Feb-18-21Initiated Piper Sandler Overweight $7
Feb-05-21Upgrade JP Morgan Underweight → Neutral
Jun-27-19Initiated Oppenheimer Outperform
Jan-04-19Initiated B. Riley FBR Buy $3
Nov-12-18Downgrade Wells Fargo Outperform → Market Perform
May-10-23 03:21PM
Apr-13-23 04:05PM
Mar-28-23 05:35PM
12:14PM Loading…
Feb-23-23 12:14PM
Feb-19-23 09:30AM
Nov-22-22 08:35AM
Nov-17-22 09:35AM
Nov-14-22 01:03PM
08:25AM Loading…
Nov-07-22 08:25AM
Oct-26-22 02:19PM
Sep-12-22 07:45AM
Aug-31-22 07:00AM
Aug-13-22 08:33AM
Aug-09-22 06:25PM
Aug-02-22 08:25AM
May-19-22 01:16PM
May-17-22 08:35AM
May-03-22 05:45PM
Apr-26-22 08:25AM
Apr-08-22 04:05PM
05:31PM Loading…
Apr-04-22 05:31PM
Mar-29-22 08:15PM
Mar-24-22 07:00AM
Mar-22-22 07:35AM
Mar-21-22 08:25AM
Mar-17-22 07:00AM
Mar-09-22 08:35AM
Mar-07-22 05:25PM
Feb-24-22 08:15AM
Feb-01-22 07:03AM
Jan-20-22 08:35AM
Jan-06-22 08:35AM
Jan-05-22 07:05AM
Dec-14-21 07:35AM
Dec-13-21 08:35AM
Dec-10-21 07:58AM
Dec-06-21 08:35AM
Nov-30-21 06:37AM
Nov-26-21 08:30AM
Nov-22-21 08:35AM
Nov-02-21 06:15PM
Oct-26-21 07:35AM
Oct-18-21 05:22PM
Oct-01-21 09:27AM
Sep-13-21 08:35AM
Sep-07-21 07:35AM
Sep-02-21 08:35AM
Aug-23-21 08:32AM
Aug-04-21 12:00PM
Aug-03-21 08:00AM
Aug-02-21 06:07PM
Jul-31-21 02:48PM
Jul-28-21 12:05PM
Jul-27-21 10:40AM
Jul-22-21 03:03PM
Jul-20-21 08:35AM
Jun-14-21 08:35AM
Jun-03-21 04:39AM
May-28-21 04:17AM
May-13-21 06:35PM
May-06-21 07:35AM
May-05-21 08:35AM
May-03-21 03:01PM
Apr-27-21 08:35AM
Apr-13-21 08:59AM
Mar-29-21 03:22AM
Mar-19-21 08:47AM
Mar-16-21 05:35PM
Mar-10-21 08:35AM
Mar-09-21 04:01PM
Mar-02-21 08:35AM
Feb-20-21 07:40AM
Feb-18-21 10:02AM
Feb-12-21 08:30AM
Feb-11-21 04:01PM
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.